JP2008526706A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008526706A5 JP2008526706A5 JP2007548771A JP2007548771A JP2008526706A5 JP 2008526706 A5 JP2008526706 A5 JP 2008526706A5 JP 2007548771 A JP2007548771 A JP 2007548771A JP 2007548771 A JP2007548771 A JP 2007548771A JP 2008526706 A5 JP2008526706 A5 JP 2008526706A5
- Authority
- JP
- Japan
- Prior art keywords
- prevention
- treatment
- disorder
- general formula
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000002265 prevention Effects 0.000 claims 6
- 150000001875 compounds Chemical class 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 2
- 208000028698 Cognitive impairment Diseases 0.000 claims 2
- 206010010904 Convulsion Diseases 0.000 claims 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- 208000028017 Psychotic disease Diseases 0.000 claims 2
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 claims 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 claims 2
- 208000010877 cognitive disease Diseases 0.000 claims 2
- 230000001149 cognitive effect Effects 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims 1
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 1
- 208000020925 Bipolar disease Diseases 0.000 claims 1
- 208000032841 Bulimia Diseases 0.000 claims 1
- 206010006550 Bulimia nervosa Diseases 0.000 claims 1
- 206010006895 Cachexia Diseases 0.000 claims 1
- 206010012335 Dependence Diseases 0.000 claims 1
- 206010019196 Head injury Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 206010021143 Hypoxia Diseases 0.000 claims 1
- 208000026139 Memory disease Diseases 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 208000019022 Mood disease Diseases 0.000 claims 1
- 208000012902 Nervous system disease Diseases 0.000 claims 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims 1
- 206010033664 Panic attack Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 206010039966 Senile dementia Diseases 0.000 claims 1
- 208000022531 anorexia Diseases 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 230000036528 appetite Effects 0.000 claims 1
- 235000019789 appetite Nutrition 0.000 claims 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 1
- 229940049706 benzodiazepine Drugs 0.000 claims 1
- 230000037396 body weight Effects 0.000 claims 1
- 208000015114 central nervous system disease Diseases 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 229960003920 cocaine Drugs 0.000 claims 1
- 230000019771 cognition Effects 0.000 claims 1
- 230000037410 cognitive enhancement Effects 0.000 claims 1
- 230000036461 convulsion Effects 0.000 claims 1
- 206010061428 decreased appetite Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 206010013663 drug dependence Diseases 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 230000037406 food intake Effects 0.000 claims 1
- 235000012631 food intake Nutrition 0.000 claims 1
- 208000013403 hyperactivity Diseases 0.000 claims 1
- 230000007954 hypoxia Effects 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 229960002715 nicotine Drugs 0.000 claims 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims 1
- 229940005483 opioid analgesics Drugs 0.000 claims 1
- 208000019906 panic disease Diseases 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 208000019116 sleep disease Diseases 0.000 claims 1
- 208000011117 substance-related disease Diseases 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP04380288A EP1676842A1 (en) | 2004-12-30 | 2004-12-30 | Nitro-substituted phenyl-piperazine compounds, their preparation and use in medicaments |
| PCT/EP2005/014191 WO2006069808A2 (en) | 2004-12-30 | 2005-12-29 | Nitro-substituted phenyl-piperazine compounds, their preparation and use in medicaments |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008526706A JP2008526706A (ja) | 2008-07-24 |
| JP2008526706A5 true JP2008526706A5 (enExample) | 2009-02-19 |
Family
ID=34931899
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007548771A Pending JP2008526706A (ja) | 2004-12-30 | 2005-12-29 | ニトロ置換フェニル−ピペラジン化合物、それらの調製及び薬剤におけるそれらの使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20080176854A1 (enExample) |
| EP (2) | EP1676842A1 (enExample) |
| JP (1) | JP2008526706A (enExample) |
| CN (1) | CN101133042A (enExample) |
| AT (1) | ATE529415T1 (enExample) |
| CA (1) | CA2592852A1 (enExample) |
| ES (1) | ES2375817T3 (enExample) |
| MX (1) | MX2007007688A (enExample) |
| WO (1) | WO2006069808A2 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2477604A1 (en) | 2002-03-13 | 2003-09-25 | Signum Biosciences, Inc. | Modulation of protein methylation and phosphoprotein phosphate |
| US7968538B2 (en) * | 2005-01-25 | 2011-06-28 | Galenea Corp. | Substituted arylamine compounds and methods of treatment |
| US7923041B2 (en) | 2005-02-03 | 2011-04-12 | Signum Biosciences, Inc. | Compositions and methods for enhancing cognitive function |
| EP1843734A4 (en) | 2005-02-03 | 2008-09-10 | Signum Biosciences Inc | COMPOSITIONS AND METHOD FOR INTENSIFYING COGNITIVE FUNCTIONS |
| EP2020230B1 (en) | 2007-08-01 | 2011-01-19 | Laboratorios del Dr. Esteve S.A. | Combination of at least two 5-HT6-Ligands |
| CN102014897B (zh) | 2008-04-21 | 2015-08-05 | 西格纳姆生物科学公司 | 化合物、组合物和其制备方法 |
| GB201002563D0 (en) * | 2010-02-15 | 2010-03-31 | Cambridge Entpr Ltd | Compounds |
| FR2976942B1 (fr) * | 2011-06-23 | 2013-07-12 | Metabolys | Derives de piperazine, leurs procedes de preparation et leurs utilisations dans le traitement de l'insulinoresistance |
| JP5949070B2 (ja) * | 2012-04-03 | 2016-07-06 | Jsr株式会社 | 液晶配向剤、液晶配向膜及び液晶表示素子 |
| HK1215256A1 (zh) | 2012-11-20 | 2016-08-19 | Vertex Pharmaceuticals Incorporated | 用作吲哚胺2，3-二氧化酶的抑制劑的化合物 |
| US11459308B2 (en) | 2016-12-05 | 2022-10-04 | Microbiotix, Inc. | Broad spectrum inhibitors of filoviruses |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2712591B1 (fr) * | 1993-11-19 | 1996-02-09 | Pf Medicament | Nouvelles arylpipérazines dérivées d'indole, leur préparation et leur utilisation thérapeutique. |
| JP4597480B2 (ja) * | 2001-05-11 | 2010-12-15 | プロキシマゲン・リミテッド | 肥満、ｉｉ型糖尿病およびｃｎｓ疾患の処置のための新規アリールスルホンアミド化合物 |
| EP1412325A1 (en) * | 2001-06-11 | 2004-04-28 | Biovitrum Ab | Substituted sulfonamide compounds, process for their use as medicament for the treatment of cns disorders, obesity and type ii diabetes |
| GB0305575D0 (en) * | 2003-03-11 | 2003-04-16 | Glaxo Group Ltd | Novel compounds |
| US8362264B2 (en) * | 2003-08-22 | 2013-01-29 | Dendreon Corporation | Compositions and methods for the treatment of disease associated with Trp-p8 expression |
| ATE437864T1 (de) * | 2004-10-22 | 2009-08-15 | Janssen Pharmaceutica Nv | Aromatische amide als hemmer der c-fms-kinase |
| US7968538B2 (en) * | 2005-01-25 | 2011-06-28 | Galenea Corp. | Substituted arylamine compounds and methods of treatment |
-
2004
- 2004-12-30 EP EP04380288A patent/EP1676842A1/en not_active Withdrawn
-
2005
- 2005-12-29 ES ES05824122T patent/ES2375817T3/es not_active Expired - Lifetime
- 2005-12-29 JP JP2007548771A patent/JP2008526706A/ja active Pending
- 2005-12-29 MX MX2007007688A patent/MX2007007688A/es not_active Application Discontinuation
- 2005-12-29 AT AT05824122T patent/ATE529415T1/de not_active IP Right Cessation
- 2005-12-29 CA CA002592852A patent/CA2592852A1/en not_active Abandoned
- 2005-12-29 WO PCT/EP2005/014191 patent/WO2006069808A2/en not_active Ceased
- 2005-12-29 US US11/813,247 patent/US20080176854A1/en not_active Abandoned
- 2005-12-29 CN CNA2005800488245A patent/CN101133042A/zh active Pending
- 2005-12-29 EP EP05824122A patent/EP1851210B1/en not_active Expired - Lifetime
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008524262A5 (enExample) | ||
| JP2009538867A5 (enExample) | ||
| JP2008526706A5 (enExample) | ||
| JP2008044931A5 (enExample) | ||
| DE69705608D1 (de) | Tropanderivate, deren herstellung und verwendung | |
| HRP20090640T1 (hr) | Kristalinični oblici (r)-8-kloro-1-metil-2,3,4,5-tetrahidro-1h-3-benzazepin hidroklorida | |
| EA200970310A1 (ru) | Сульфонилпиразольные и сульфонилпиразолиновые производные карбоксамидина как антагонисты 5-ht | |
| JP2005524713A5 (enExample) | ||
| JP2012508275A5 (enExample) | ||
| JP2009538869A5 (enExample) | ||
| UA105629C2 (uk) | Похідні арилсульфоніл піразолін карбоксамідину як антагоністи 5-нт6 | |
| JP2009538870A5 (enExample) | ||
| JP2005521671A5 (enExample) | ||
| WO2007076875A3 (en) | Compounds acting on the serotonin transporter | |
| JP2006520766A5 (enExample) | ||
| WO2009003868A3 (en) | 2 -imidazolines having a good affinity to the trace amine associated receptors (taars) | |
| NO20091480L (no) | Aminometyl-2-imidazoler med affinitet mot sporamin-assosierte reseptorer | |
| JP2008530171A5 (enExample) | ||
| JP2015521642A5 (enExample) | ||
| JP2009537599A5 (enExample) | ||
| JP2019511548A5 (enExample) | ||
| TW200813006A (en) | New compounds III | |
| JP2005530814A5 (enExample) | ||
| WO2003016274A3 (en) | 2-substituted piperidines that are ligands for monoamine receptors and transporters | |
| TW200833327A (en) | 4-imidazolines as TAAR's ligands |